Blog
Announcing IPC’s New Leadership for 2025.
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Read MoreThe 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…
Read MoreDr. Catherine Smith explores how biomarkers can enhance health and improve comorbidity outcomes, specifically focusing…
Watch VideoThis report from the 53rd Annual ESDR Meeting in Lisbon covers key presentations on psoriasis, including updates from…
Read MoreThe 53rd Annual European Society for Dermatological Research (ESDR) Meeting was held in Lisbon, Portugal, from…
View ReportJoin Dr. Catherine Smith, Professor of Dermatology, clinician, and a key member of the International Psoriasis Council…
Read MoreEUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH ANNUAL MEETING (ESDR) | LISBON, PORTUGAL Program chairs: Johann…
Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving…
Read MoreDr. Catherine Smith discusses the science and practice, framework, and implementation of therapeutic drug monitoring…
Watch VideoThe spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address…
Read MoreDr. Smith reviews how biomarkers can be used to identify patients at risk for severe disease and those who would…
Watch VideoUnder the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank…
Read MoreMeet the three new key opinion leaders who have been elected to join our board.
Read MoreHeld virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100…
Read MoreThe registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects…
Read MoreView Report
The entry of biosimilar forms of biopharmaceutical therapies for the treatment of psoriasis and other immune-mediated…
View Report| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.